药品注册申请号:021892
申请类型:NDA (新药申请)
申请人:SALIX PHARMS
申请人全名:SALIX PHARMACEUTICALS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 OSMOPREP SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE TABLET;ORAL 0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Yes No AB 2006/03/16 2006/03/16 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2018/11/29 SUPPL-14(补充) Approval Labeling STANDARD
2016/06/21 SUPPL-13(补充) Approval Manufacturing (CMC) STANDARD
2015/09/15 SUPPL-12(补充) Approval Manufacturing (CMC) STANDARD
2012/10/05 SUPPL-6(补充) Approval Labeling STANDARD
2011/12/09 SUPPL-9(补充) Approval REMS N/A
2009/10/13 SUPPL-4(补充) Approval Labeling STANDARD
2009/03/25 SUPPL-3(补充) Approval Labeling 901 REQUIRED
2008/12/10 SUPPL-2(补充) Approval Labeling STANDARD
2007/09/18 SUPPL-1(补充) Approval Labeling STANDARD
2006/03/16 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 7687075 2028/06/22 Y Y PDF格式
001 5616346 2013/05/18 Y U-715 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 NP 2009/03/16**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 剂型/给药途径:TABLET;ORAL 规格:0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021892 001 NDA OSMOPREP SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE TABLET;ORAL 0.398GM;1.102GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Discontinued Yes No AB 2006/03/16 SALIX PHARMS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database